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penetrant mutations in a number of genes
controlling appetite and body weight.
Marenne et al. identify three genes with
mutations with variable penetrance in a
continuum of causality in childhood
obesity, and demonstrate that variants in
PHIP repress POMC transcription.ll
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https://doi.org/10.1016/j.cmet.2020.05.007SUMMARYObesity is genetically heterogeneous with monogenic and complex polygenic forms. Using exome and tar-
geted sequencing in 2,737 severely obese cases and 6,704 controls, we identified three genes (PHIP, DGKI,
andZMYM4) with an excess burden of very rare predicted deleterious variants in cases. In cells, we found that
nuclear PHIP (pleckstrin homology domain interacting protein) directly enhances transcription of pro-opio-
melanocortin (POMC), a neuropeptide that suppresses appetite. Obesity-associated PHIP variants
repressed POMC transcription. Our demonstration that PHIP is involved in human energy homeostasis
through transcriptional regulation of central melanocortin signaling has potential diagnostic and therapeutic
implications for patients with obesity and developmental delay. Additionally, we found an excess burden of
predicted deleterious variants involving genes nearest to loci from obesity genome-wide association studies.
Genes and gene sets influencing obesity with variable penetrance provide compelling evidence for a contin-
uum of causality in the genetic architecture of obesity, and explain some of its missing heritability.Context and Significance
Obese children are often stigmatized and experience health problems such as diabetes and heart disease in later life.
Finding the cause of their obesity may lead to new treatments. In some cases, faulty genes underly severe childhood
obesity. In this study, researchers in the United Kingdom and their colleagues aimed to discover new genes linked to severe
childhood obesity and found three candidates. One gene, PHIP, affected childhood obesity with learning difficulties. They
demonstrate that PHIP works by controlling another gene, POMC, which is known to regulate appetite. This finding means
that children with faults in the gene PHIPmay benefit from existing treatments. Further studies will be required to fully eval-
uate these genes in a broader context.
Cell Metabolism 31, 1107–1119, June 2, 2020 ª 2020 The Author(s). Published by Elsevier Inc. 1107
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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The rising prevalence of obesity is largely driven by the con-
sumption of high-calorie foods and reduced levels of physical
activity at work and in leisure time, which contribute to sustained
positive energy balance and weight gain. However, family, twin,
and adoption studies have consistently demonstrated that 40%–
70% of the variation in body weight in a given environment is
attributable to genetic variation within the population (Allison
et al., 1996). As such, finding even a single gene that contributes
to the regulation of body weight is important as it provides in-
sights into the mechanisms underlying the development of
obesity and may identify potential targets for future weight loss
therapy.
To date, several different approaches have been used to iden-
tify genes involved in human energy homeostasis. Candidate
gene studies led to the identification of very rare variants that
cause monogenic forms of severe obesity mostly by impacting
the function of proteins involved in the central leptin-melanocor-
tin pathway (Doche et al., 2012; O’Rahilly and Farooqi, 2008;
Saeed et al., 2018; van der Klaauw and Farooqi, 2015). These
findings have had diagnostic value for patients and have paved
the way for stratified therapy as seen with the treatment of
congenital leptin deficiency by recombinant leptin (Farooqi
et al., 1999) and of POMC and LEPR deficiency by the melano-
cortin 4 receptor (MC4R) agonist setmelanotide (Cle´ment et al.,
2018; K€uhnen et al., 2016).
By focusing on more common forms of genetic variation (mi-
nor allele frequency [MAF] > 5%) in population-derived cohorts,
genome-wide association studies (GWAS) have identified over
250 loci that are associated with body mass index (BMI) and/or
obesity (defined as a BMI > 30 kg/m2), mostly through modest
effects on neuronal genes (Akiyama et al., 2017; Grarup et al.,
2018; Justice et al., 2017; Minster et al., 2016; Turcot et al.,
2018; Locke et al., 2015). While cumulatively these approaches
have provided a framework for understanding the genetic archi-
tecture of weight regulation and susceptibility to obesity, a sub-
stantial proportion of the heritability of human obesity (including
severe childhood-onset obesity) has yet to be explained. There is
no biological reason why genetic risk factors for common com-
plex traits/diseases should fall neatly into these two categories,
as we (Barroso andMcCarthy, 2019) and others (Katsanis, 2016;
Marouli et al., 2017) have suggested. We therefore hypothesize
that variants that contribute to this ‘‘missing heritability’’ in
obesity will include a range of allele frequencies and effect sizes
in a continuum of causality (Katsanis, 2016), as seen for other
complex traits (Marouli et al., 2017), and explore this in the
work we present here.
RESULTS
Rare Variants Implicate Three New Genes in Human
Energy Homeostasis
Here, we studied a cohort of European ancestry individuals with
severe childhood-onset obesity (SCOOP) in whom known
causes of monogenic obesity, such as congenital leptin defi-
ciency and MC4R mutations, had been excluded (STAR
Methods). Children were recruited into the cohort if they had a
BMI standard deviation score (BMI SDS) greater than three1108 Cell Metabolism 31, 1107–1119, June 2, 2020and age of onset below 10 years (Wheeler et al., 2013) (STAR
Methods). Our study design, focused on early-onset severe
obesity, was aimed at increasing power to identify genes with
an excess burden of rare, functionally significant variants with
moderate to large effects on the phenotype (STAR Methods).
We analyzed whole-exome sequencing (WES) data from 927
SCOOP cases (Hendricks et al., 2017; Walter et al., 2015) and
4,057 UK healthy blood donors from the INTERVAL cohort (stage
1; STARMethods; Figures 1 and S1). To test for different genetic
effects, we performed single-variant (Table S1) and three nested
gene-based analyses: (1) burden of very rare (MAF < 0.025%)
predicted loss-of-function (LOF) variants (LOF analysis), (2)
burden of very rare (MAF < 0.025%) predicted deleterious vari-
ants by five different in silico programs (LOF and missense
[STRICT] analysis), and (3) SKAT-O analysis of variants with
MAF < 1% and predicted deleterious by a single program (LOF
and missense [BROAD] analysis) (Figures 1, S1, and S2; Tables
S2A–S2C; STAR Methods).
We identified nine genes with an excess burden of variants
from LOF, STRICT, and BROAD analyses in cases versus con-
trols, meeting the arbitrary threshold of p < 104, which we
took forward for stage 2 analysis (Figure 1; STAR Methods;
Tables S2A–S2C). Targeted sequencing was performed in an
additional unrelated 1,810 SCOOP cases and 2,647 controls
from the Fenland cohort (stage 2), and validation of reported var-
iants was undertaken by Sanger sequencing (STAR Methods).
Validated variants from stage 1 and stage 2 results were com-
bined in meta-analysis. Directionally consistent association
with obesity in stage 2, and stronger p values from stage 1 + 2
in either LOF or STRICT analysis was detected in three genes.
For each gene, we highlight the most significant association
result: pmeta-LOF = 1.23 3 10
5 PHIP (pleckstrin homology
domain interacting protein), pmeta-STRICT = 7.933 10
4 DGKI (di-
acylglycerol [DAG] kinase iota), and pmeta-LOF = 3.19 3 10
7
ZMYM4 (zinc-finger-MYM-type-containing 4) (Table 1). ZMYM4
results are significant after Bonferroni correction for all genes
in the genome (p < 2.5 3 106). In all, we see strong evidence
of winner’s curse with much larger odds ratios in stage 1,
compared to stage 2 analysis.
In a fourth gene, ZNF32 (zinc-finger protein 32), very rare pre-
dicted deleterious variants were only observed in stage 1 cases
(pSTRICT = 2.843 10
5; Table 1). ZNF32 is a zinc-finger protein of
uncharacterized function and with a ubiquitous expression
pattern (Figure S3A). We attempted to gain independent evi-
dence of its role in obesity by generating an engineered mouse
mutant; however, homozygous ZNF32 em1(IMPC)Wtsi do not
display any obvious phenotype (data not shown). We present
our results here to invite others to explore this gene in their co-
horts, but at this stage we feel the evidence is insufficient to
link this gene with obesity.
Though not independent, analysis using stage 1 cases and
external controls (to increase sample size) also provides support
(PHIP, pLOF = 4.9 3 10
4; DGKI, pSTRICT = 0.10; ZMYM4, pLOF =
7.10 3 105; ZNF32, pSTRICT = 2.14 3 10
2; Table S3; STAR
Methods). To further strengthen the evidence for or against the
role of these genes in extreme obesity, we examined 431 adults
with BMI > 40 kg/m2 from the UK10K project (approximately
equivalent to the BMI > 3 SDs used to define severe obesity in
children in SCOOP) and 984 non-overlapping adult controls
Figure 1. Flow Diagram of Approach and Headline Results
The overall analysis and main results from this study. Whole-exome sequence data from SCOOP and INTERVAL participants were analyzed as single-variant,
gene-base, and gene set analyses. Overall, 48 variants from single-variant and gene-based analysis and 9 genes from gene-based analysis were identified and
taken forward to stage 2 validation, by genotyping or targeted-sequenced. Combined stage 1 and stage 2 significant results were found in three genes (PHIP,
DGKI, and ZMYM4), which were taken for functional follow-up. In parallel, gene set analysis performed on five primary gene sets (obesity, syndromic obesity,
DDG2P, Constrained [pLI > 0.9], Unconstrained [pLI% 0.9], and Genes Mapping to known Obesity or BMI GWAS loci) is represented. The strongest enrichment,
which was detected in loss-of-function constrained genes (pLI > 0.9) mapping to obesity or BMI-associated GWAS loci, is shown (Genes in GWAS loci, pLI > 0.9).
Related to Figure S1.
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1110 Cell Metabolism 31, 1107–1119, June 2, 2020from the 1958 Birth Cohort (STAR Methods). We identified be-
tween 0 and 2 STRICT or LOF very rare variants in these four
genes in adult cases and 0–3 STRICT or LOF very rare variants
in adult controls, and while the 95% CIs overlapped estimates
from children, they also included the null (Table S4). Single-
variant and BROAD stage 1 + 2 combined results did not yield
additional significant association results (Tables 2, S5, and
S6A; STAR Methods).
Finally, through analysis focused on 43 genes previously
known to harbor mutations causal of monogenic/syndromic
obesity (Table S8A), we find 12 genes have nominal evidence
of a burden of BROAD, STRICT, or LOF very rare variants in
our obese cases compared to controls (stage 1 samples, p <
0.05; Table S2D).
PHIP Variants Are Associated with Obesity with and
without Development Delay
PHIP is of particular interest, as deletions and frameshift muta-
tions in this gene have been reported in patients with develop-
mental delay, intellectual disability, and dysmorphic features,
and in some cases, patients were reported to be overweight
(de Ligt et al., 2012; Jansen et al., 2018; Webster et al., 2016).
In keeping with previous reports, some probands in SCOOP
had learning difficulties and dysmorphic features (Table 3).
Repeat analysis of our obesity cases stratified by the pres-
ence/absence of developmental delay demonstrated a very
strong association of a burden of PHIP very rare LOF variants
with obesity in the presence of developmental delay
(ORLOF_stage1+2 = 95.01, CI95 = 5.11,1765.21, pLOF_stage1+2 =
3.19 3 1010; Figure 2). We also found moderate evidence for
association with obesity in the absence of developmental delay
(ORLOF_stage1+2 = 26.95, CI95 = 1.39,521.79, pLOF_stage1+2 =
0.0006; Figure 2; Table S7). Where samples from one or both
parents were available, we found that 3 probands had inherited
the variant from an overweight/obese parent (A389T, R409C,
and T1506A), 3 variants (R250X, F1414S, and c.3536-
4_3540delTTAGATATT) were found de novo, and one variant
(found in two unrelated probands) was inherited from a normal
weight parent (T1506A) (Table 3). The absence of severe obesity
in some family members carrying PHIP STRICT missense and
LOF variants, the absence of developmental delay in some pro-
bandswith LOFmutations (Table 3), and the presence of STRICT
missense variants in control participants without obesity (6/9
controls who were carriers of very rare STRICT variants had a
BMI < 30 kg/m2) suggest variable penetrance.
PHIP Regulates POMC Transcription in Cells
We performed experiments in cells to explore the potential
mechanisms by which PHIP might regulate body weight and to
test the functional consequences of the 17 very rare coding var-
iants found in cases and controls (Figure 3A). Human PHIP exists
as two isoforms with distinct cellular localizations (Figure 3B). A
short cytoplasmic PHIP (104 kDa) isoform interacts with insulin
receptor substrate (IRS)-1 and -2 and is required for insulin
and insulin-like growth factor (IGF-1) signaling (Farhang-Fallah
et al., 2000). A long (230-kDa) PHIP isoform is exclusively
localized in the nucleus. Nuclear PHIP (synonyms DDB1- and
CUL4-associated factor 14 [DCAF14] or replication initiation
determinant protein [REPID]) is known to bind directly to
Table 2. Burden of Rare Variants (MAF < 1%) from BROAD Analysis Enriched in Obese Cases Compared to Controls
Stage 1 Stage 2 Stage 1 + Stage 2
Gene p Value Number of
Variants/Case
Alleles/Control
Alleles
OR p Value Number of
Variants/Case
Alleles/Control
Alleles
OR p Value OR
PHIP 0.0059 38/14/29 2.11 [1.12–4] 0.0086 22/18/9 2.95 [1.33–6.57] 4.58 3 104 2.4 [1.5–3.84]
DGKI 0.0134 30/18/40 1.97 [1.13–3.44] 0.8910 27/14/20 1.03 [0.52–2.03] 0.0998 1.35 [0.88–2.07]
ZMYM4 0.071 34/25/70 1.56 [0.99–2.47] 0.4911 25/57/89 0.94 [0.68–1.31] 0.4493 1.38 [1.06–1.8]
ZNF32 0.0033 6/4/2 8.76 [1.6–47.81] 1.0000 3/2/3 0.98 [0.16–5.85] 0.0869 3.53 [1.08–11.58]
Stage 1 included 927 SCOOP cases and 4,057 INTERVAL controls; stage 2 included 1,810 obesity cases and 2,647 Fenland controls.
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OPEN ACCESSArticlechromatin to promote initiation of DNA replication and gene tran-
scription (Jang et al., 2018). It alsomediates effects on post-natal
growth (Li et al., 2010), b cell growth, regulation, and survival
(Podcheko et al., 2007). Three variants affected splice donor/
acceptor sites and were predicted in silico to lead to exon skip-
ping/intron retention and result in LOF of the long isoform ofPHIP
(Figure 3A).
Here, using immunoprecipitation, we showed that cyto-
plasmic PHIP interacts with IRS-2 in cells stimulated with leptin
(Figure S4A); however, this interaction is not required for and
does not modulate leptin-mediated phosphorylation of STAT3
or ERK1/2, key signaling pathways involved in energy homeosta-
sis (Figure S4B). We next investigated whether nuclear PHIP
could directly affect the transcription of pro-opiomelanocortin
(POMC), a neuropeptide that mediates the appetite-suppressing
effects of leptin. Using a POMC luciferase reporter assay, we
found that wild-type (WT) PHIP potentiated POMC transcription
in the absence of leptin (Figure 3C); all PHIP mutants decreased
POMC transcription (Figure 3D). Seven mutants repressed
POMC transcription below levels seen for the null mutation
R250X. In co-transfection experiments with varying concentra-
tions of WT and mutant PHIP, four of these mutants (T289P,
D594E, Q1343X, and R1505Q) exert a dominant-negative effect,
repressing POMC transcription by WT PHIP in a dose-depen-
dent manner (Figure 3E). Using fluorescent microscopy, we
found that most mutants did not alter cellular localization of
PHIP, although variants found in cases led to a significant
decrease in the ratio of nuclear:cytoplasmic PHIP compared to
controls (p = 0.004) (Figures 3F–3H, S4, and S5). This finding
suggests that a reduction in the amount of nuclear PHIP available
to enhance POMC transcription (with or without leptin) may
contribute to the development of obesity. Leptin stimulation
rescued the effects of some, but not all, PHIP mutants on
POMC transcription (Figure S4).
PHIP Variant Carriers Exhibit Maladaptive Behaviors
Phip null mice exhibit a 40% growth deficit by weaning, develop
hypoglycemia, and do not survive beyond 4–5 weeks (Li et al.,
2010). In keeping with the growth phenotype seen in null mice,
5 of 13 PHIP variant carriers on whom data was available (Table
3) were born with low birthweight for gestational age. In some
cases, there was evidence of rapid catch-up growth in early
childhood (R409C), whereas other probands remained short
(Q1343X) (Table 3). In addition, some variant carriers reportedhyperphagia and developed insulin resistance and early type 2
diabetes (Table 3). Maladaptive behaviors, reminiscent of those
seen in carriers of variants in SH2B1 (Doche et al., 2012), another
PH domain-containing protein involved in leptin and brain-
derived neurotrophic factor (BDNF)-mediated signaling, were re-
ported in several probands in this study and in previous clinical
case series. Taken together, the combined genetic and func-
tional data provide compelling evidence that PHIP is involved
in human obesity with and without developmental delay. PHIP
variants are likely to impact the transcription of multiple down-
stream target genes, which may in part explain the variability in
clinical phenotype observed, which is not simply explained by
the results of functional assays used.
DGKI Is Associated with Obesity in Humans and Fat
Mass in Mice
Next, we studied DGKI, which is expressed in numerous brain
regions (hippocampus, hypothalamus, caudate nucleus, and
cortex) and in the thyroid (STAR Methods; Figure S3B), making
it a plausible DGK isoform to be involved in energy homeostasis
and metabolism. DAG kinases terminate DAG signaling and are
important regulators of long-term potentiation and long-term
depression, cellular mechanisms involved in synaptic plasticity
(Lee et al., 2016). Common variants in the DGKI gene region
have been associated with dyslexia (Matsson et al., 2011); the
patient with the nonsense mutation (Q265X) was reported to
have speech and language delay (Table 3). Delayed habituation
to novel environments has previously been reported in Dgki
knockout mice (Yang et al., 2011).
Here, we engineered mutant Dgkiem1(IMPC)Wtsi mice, and utiliz-
ing the Sanger Institute mouse phenotyping pipeline we provide
preliminary evidence supporting a role of Dgki in energy homeo-
stasis in mice (STAR Methods). Phenotyping of homozygous
Dgkiem1(IMPC)Wtsi mice suggests these mice have increased fat
mass and fat percentage, lower bonemineral density, and higher
plasma glycerol (males) (STAR Methods; Figures S6 and S7).
However, metabolic phenotyping after exposure to a high-fat
diet will be required to further investigate the impact of this
gene deletion in energy homeostasis and to gain mechanistic
insights.
ZMYM4 Is a Novel Gene Linked to Human Obesity
ZMYM4 encodes a poorly characterized protein with a predicted
central zinc-finger domain, a proline-rich region, and aCell Metabolism 31, 1107–1119, June 2, 2020 1111
Table 3. Phenotypes Seen in Carriers of Rare Variants in PHIP, DGKI, and ZMYM4
Variant
Age
(Years) Sex
BMI
(SDS)
Height
(SDS)
Bwt
SDS
Learning
Difficulties
Dysmorphic
Features
Autistic
Features Hyperactivity Aggression
Anxiety or
Depression
Insulin
(pmol/L)
Glucose
(mmol/L)
PHIP
R250Xa 6 F 25 (3.6) 111 (0.9) 0.6
T289P 7.7 F 34 (4.2) 133 (1.3) 1.5 U U 134 3.8
A389T 5.1 F 40 (6.0) 114 (1.1) 2.2 146 4.7
A389Tb 46 M 54 173 171 5.3
R409C 1.4 F 24 (3.7) 84 (1.6) 2.9 U U U U 47 5.1
R409Cb 34 M 38 175
R721X 44.3 F 74 150 @ 9.1
Q1343X 17.2 F 43 (3.8) 151 (2.1) 0.1 U U 208c 5.9
F1414Sa 20.7 M 40 188 0.9 U U U U U 398c 6
K1443T
fsX11
7.6 F 35 (4.3) 119 (1.1) 1.7 U U 42 4.4
T1506A 2.4 F 23 (3.8) 102 (3.8) 1.6 U 292 5.8
T1506Ab 44 M 21
T1506A 15 M 46 (4.0) 168 (0.1) 0 U 98 5.1
T1506Ab 54 M 29
R1718S 22.7 M 40 170 1.8 100 5.4
c.823-
2A>G
7.9 M 27 (3.5) 135 (1.4) 0.3 U U U 57 5.5
c.1524+
1G>T
15.5 M 35 (3.2) 176 (0.6) 0.23 U U 154 5.2
c.3536-4
_3540
delTTA
GATATTa
13.1 F 49 (4.2) 161 (0.7) 0.9 U 144 5.3
DGKI
D833N 15.3 F 45 (4.0) 166 (0.5) 0.2 144 4.6
L430R 9.1 F 26 (2.9) 132 (0.2) 1.3
Q265X 3.6 M 22 (3.6) 113 (3.3) 0.8 Us 32 4.7
L192F 12.6 M 31 (3.1) 151 (0.1) 0.1 41 3.1
ZMYM4
N89S 15.5 F 39 (3.5) 161 (0.4) 0.1 U 136 4.6
K163R
fsx10
11.1 M 28.3 (3.0) 152 (1.2) 0.1 24 4.2
R379C 1.2 F 26 (4.5) 84 (3.0) 0.5 36
K387N 7.8 M 25 (3.3) 131 (0.8) 0.6 U 30 3.9
M, male; F, female. BMI (kg/m2) shown for adults with age- and gender-adjusted standard deviation scores (SDS) shown in brackets for children under
18 years of age at referral. Height in cm (SDS). Birthweight (Bwt) SDS adjusted for gestational age.U indicates reported presence of a phenotype.
Fasting values for glucose and insulin reported: normal range for fasting plasma insulin = 0–60 pmol/L. @, on medication for type 2 diabetes. Speech
and language delay represented asUs.
aDe novo inheritance established by genotyping both parents.
bRare coding in family member.
cPresence of acanthosis nigricans (skin marker of insulin resistance).
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OPEN ACCESS ArticleC-terminal DUF3504 domain, the latter suggesting it may func-
tion as a transcriptional activator or repressor (Kojima and Jurka,
2011). It has a broad tissue expression pattern (STAR Methods;
Figure S3C), is predicted to be an LOF intolerant gene (pLi = 1.00)
(Lek et al., 2016), and has not been previously linked to obesity or
metabolism. LOF intolerant genes are those in which strong
negative selection has meant that the gene has fewer LOFmuta-
tions in the general population than expected, presumably1112 Cell Metabolism 31, 1107–1119, June 2, 2020because of their impact on reproductive fitness. Other than
mild learning difficulties, there were no distinctive phenotypes
other than severe obesity in variant carriers (Table 3).
To gain further insight into ZMYM4 function, we generated mice
homozygous for the Zmym4em1(IMPC)Wtsi allele. In keeping with
ZMYM4 being an LOF intolerant gene, we found that homozygous
Zmym4em1(IMPC)Wtsi mice are pre-weaning lethal. No homozygous
mice were detected from 56 offspring, while 14 from 56 offspring
Figure 2. Detailed PHIP Association Results
Results for BROAD, STRICT, and LOF analyses for PHIP variants are shown
overall (gray), in obese patients with developmental delay (red), and in obese
patients without developmental delay (blue). ORs are represented by di-
amonds with 95% CI shown by dashed lines. Across all analyses, there is a
trend for greater ORs for increasing stringency of the test (BROAD < STRICT <
LOF). Related to Table S7.
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Moresophisticatedmodels targetingallele loss inspecific tissuesor
detailed phenotyping in heterozygous Zmym4em1(IMPC)Wtsi mice
will be required to further elucidate the physiological role of
this gene.
Genes in BMI GWAS Loci Are Enriched for Very Rare
Predicted Deleterious Variants in Severe Obesity
Lastly, we investigated whether particular groups of genes, as a
gene set, were enriched in very rare predicted deleterious vari-
ants in severe early-onset obesity cases compared to controls.
These analyses can overcome some of the power limitations
when testing genes individually: though individual genes may
have insufficient evidence of association with severe early-onset
obesity, collectively, gene sets may be shown to associate with
obesity. We performed analyses on 10 primary gene sets (Table
S8; STAR Methods).
In gene set analyses, we found that the set of 157 genes
mapping to BMI and obesity GWAS loci (GWAS set) was en-
riched for very rare functional variants in childhood obesity
cases (ORSTRICT = 1.18, CI95 = 1.03,1.18, pperm-STRICT =
1.63 3 102; ORLOF = 1.39, CI95 = 1.07,1.80, pperm-LOF =
1.39 3 102; Figure 4A; Table S9A). This provides a compel-
ling rationale for sequencing this group of genes in additional
cases and controls, to identify novel variants that may have
stronger effects on severe early-onset obesity, and which
may yield potential novel drug targets.
We also noted that genes that are normally depleted in LOF
mutations in the population, known as LOF intolerant genes
(pLI > 0.9) (Lek et al., 2016), were more common in this
GWAS set compared to all genes in the genome (33.8% versus19.1%, pChiSq-Ind = 3.11 3 10
6). In secondary analyses, we
found that this subset of 53 LOF intolerant genes among the
157 genes in the GWAS set was further enriched in very rare
deleterious variants in our obese cases compared to controls
(ORSTRICT = 1.34, CI95 = 1.14,1.58 pperm-STRICT = 8.00 3 10
4;
ORLOF = 3.54, CI95 = 1.80,6.95, pperm-LOF = 5.00 3 10
4) (Fig-
ure 4A; Table S9D). The OR for putative LOF variants in this
gene set of 53 genes was similar to the estimate for the gene
set of monogenic obesity genes (Figure 4A). This suggests
that some of these genes may harbor rare variants of poten-
tially larger effect size affecting severe childhood obesity.LOF Intolerant Genes Are Enriched in Very Rare
Deleterious Variants in Obese Cases with
Developmental Delay
As severe obesity is not normally reproductive lethal, it was sur-
prising to find that 53 LOF intolerant genes among the GWAS set
were particularly enriched for very rare deleterious variants in our
cases. To further explore these results, we stratified our cases
into those with developmental delay and those without. In this
group of 53 LOF intolerant genes in the GWAS set, enrichment
was similar whether or not obese cases had developmental
delay (Figure 4B; Table S9D).
Next, we noted that the set of all 3,488 LOF intolerant genes in
the genome (pLi > 09-set) was also significantly enriched in rare
variants in obesity cases (ORSTRICT = 1.07, CI95 = 1.02,1.13,
pperm-strict = 6.85 3 10
3; ORLOF = 1.17, CI95 = 1.07,1.27,
pperm-LOF= 3.003 10
4; Figure 4A; Table S9A). However, consis-
tent with obesity not normally being reproductive lethal, we find
most of this signal to be driven by obesity cases that also have
developmental delay (Figure 4B; Tables S9B and S9C), suggest-
ing these genesmay yield further diagnostic findings in this set of
patients. In contrast, genes that are not LOF intolerant (pLi% 0.9)
show no evidence of enrichment (Figures 4A and 4B; Tables
S9A–S9C).Rare Genetic Variation Associated with Obesity Is in the
Most Constrained Gene Sets
Many diseases that are under strong negative selection, such as
schizophrenia, have been shown to be enriched for rare, putative
deleterious genetic variation in genes that are usually con-
strained to LOF variation (pLi > 0.9). Given that obesity may
not have undergone strong negative selection, we aimed to
test whether the contribution of rare, putative deleterious genetic
variation was also observed in gene sets regardless of the level
of constraint against deleterious variation. To test this, we
assessed gene set enrichment among the deciles of missense
constrained genes where genes in the top decile are more con-
strained against missense variation (i.e., less likely to have
missense variation in the general population) and genes in the
first decile are less constrained to missense variation (i.e.,
more likely to have missense variation in the general population).
We additionally assessed the deciles of LOF constrained genes.
We did not find strong evidence of enrichment for rare delete-
rious variants beyond gene sets with the strongest constraint
against missense or LOF variation, suggesting that, at least for
extreme clinical obesity such as that studied here, enrichment
for rare putative deleterious variants is primarily in genes thatCell Metabolism 31, 1107–1119, June 2, 2020 1113
Figure 3. Functional Characterization of Obesity-Associated Variants in PHIP
(A) Mapping of human PHIP coding and splice-site variants identified in cases only (red), controls only (blue), and in cases and controls (green) on the full-length
PHIP isoform. One variant was found in two unrelated probands (underlined); some variants were found in probands who also had developmental delay (*).
(legend continued on next page)
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Figure 4. Gene Set Analysis
(A) Gene set enrichment analysis for a burden of BROAD, STRICT, and LOF variants in cases compared to controls across 10 primary gene sets. Obesity 1A
(monogenic obesity genes, 11 genes), Obesity 1B (9 genes, monogenic obesity genes where LEP and MC4R were removed), Syndromic 2 (syndromic obesity
genes, 32 genes), DDG2P 3A (developmental disorder dominant genes causal through missense or LOF mutations, 360 genes), DDG2P 3B (developmental
disorder dominant genes causal through LOF mutations 274 genes), DDG2P 3C (developmental disorders with brain abnormalities dominant genes causal
through missense or LOF mutations, 187 genes), DDG2P 3D (developmental disorders with brain abnormalities dominant genes causal through LOF mutations
147 genes), pLI > 0.9 4A (LOF intolerant genes, 3,488 genes), pLI% 0.9 4B (LOF tolerant genes, 14,753 genes), GWAS 5 (genes mapping to BMI/obesity GWAS
loci based on GWAS catalog data, 157 genes). Results for a combined subcategory of pLI > 0.9 and GWAS (4A and 5, 53 genes) are also shown. Gene sets are
described in Table S8 and detailed gene set results are in Table S9. Odds ratios (ORs, y axis) and 95%CI (dashed lines) are shown for each gene set and analysis.
(B) Odds ratios (ORs) for obesity cases with developmental delay (DD, x axis) and ORs for obesity cases without developmental delay (not DD, y axis) are shown
for each of the gene sets shown in (A). p value strength is indicated by size of the circle, for obesity DD (pink) and obesity not DD (blue) in semi-transparent circles.
LOF intolerant genes overall (4A) and all of DDG2P (3A–3D) have larger ORs and are more significantly associated with obesity DD. In contrast, GWAS genes that
are also LOF intolerant (4A&5) show equivalent ORs and statistical association with obesity DD and obesity not DD. Related to Tables S8 and S9.
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ble S9E).
DISCUSSION
Most genetic studies of obesity have to date identified very rare,
likely fully penetrant monogenic mutations causal of severe
forms of obesity, or common low-impact alleles influencing
BMI and other measures of adiposity in large population-based
cohorts. Here, by focusing our efforts on a clinical cohort of
very severe early-onset obesity cases of unknown cause, and
combining genetic evidence with functional work in cells and
in vivo, we provide evidence for a continuum of causality in the
genetic architecture of obesity. We identify three genes (PHIP,
DGKI, and ZMYM4) newly implicated in obesity, harboring very
rare predicted deleterious alleles, with intermediate effects and
penetrance between those identified through family or large-
population scale efforts.(B) Representative confocal fluorescence microscopy images showing PHIP loc
antibody against endogenous PHIP. Scale bar, 100 mm.
(C) Overexpression of WT PHIP potentiates POMC transcription in basal and lep
Welch’s correction, *p < 0.05, **p < 0.01, ***p < 0.001.
(D) Effect of human PHIP mutants on POMC transcription compared to WT in ba
comparisons to WT, *p < 0.05, **p < 0.01, ***p < 0.001.
(E) Dominant-negative effect of human PHIP mutants in POMC transcription in b
comparisons to 0 ng, *p < 0.05, **p < 0.01, ***p < 0.001.
(F) Representative confocal fluorescence microscopy images showing cytoplasm
(G) Nuclei to cytoplasm ratio of PHIP subcellular localization. n = 3, mean + SE
***p < 0.001.
(H) Nuclear to cytoplasmic ratio in variants found only in cases in comparison to c
span from the minimum to maximum values. Wilcoxon rank-sum test, **p = 0.00These findings have potential diagnostic implications. While
PHIP has previously been linked to a complex syndrome of
developmental delay, and some patients have been noted to
be overweight, the gene is not currently included on any gene
panel for diagnostic testing in obesity, nor is PHIP screening rec-
ommended in obesity syndromes. The patients we identified all
presented with severe obesity—some did have developmental
delay, but not all. We consider that this finding plus the associ-
ated molecular work identifying a mechanism by which disrup-
tion of PHIP can cause obesity (by disrupting transcription of
POMC) establishes that some patients may present with obesity
alone. While we find a broad spectrum of mutations, this
alone cannot explain the divergence in phenotypic spectrum
seen. It is likely that as PHIP affects transcriptional regulation,
specific mutations may exert a variable effect clinically. Our
data suggest that PHIP should be included in genetic testing
recommended in clinical guidelines as part of the assessment
of severe childhood-onset obesity, particularly in the presencealization in the nucleus and the cytoplasm of COS7 cells. Blue, nuclei; green,
tin-stimulated conditions. n = 15, mean + SEM, two-tailed unpaired t test with
sal conditions. n = 4–6, mean + SEM, ordinary one-way ANOVA with multiple
asal conditions. n = 3, mean + SEM, ordinary one-way ANOVA with multiple
ic protein localization of PHIP mutants in basal conditions.
M, two-tailed unpaired t test with Welch’s correction, *p < 0.05, **p < 0.01,
ontrols. Lines represent medians and crosses represent means. Dashed lines
4. Related to Figures S4 and S5.
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OPEN ACCESS Articleof developmental delay (Styne et al., 2017). These findings may
also inform the mechanism-based treatment of PHIP variant car-
riers with a melanocortin receptor agonist currently in clinical tri-
als, which leads to significant weight loss in severe obesity due
to complete POMC deficiency (K€uhnen et al., 2016). A subset
of PHIP variant carriers may also benefit from treatment with re-
combinant leptin, leptin mimetics, or sensitizers.
Little is known of the biological function of DGKI or ZMYM4, or
the mechanism through which they influence energy homeosta-
sis. Their discovery is therefore important as it provides new
avenues for future biological exploration, and establishes a new
link between these genes and as yet undescribedmolecular path-
ways implicated in human metabolism and energy homeostasis.
Our results also demonstrate the challenge in identifying novel
molecular links between heterogeneous complex diseases and
very rare variants that may not be fully penetrant. From a statis-
tical standpoint, the burden of proof is high, possibly requiring in
the order of tens of thousands of cases to attain established
Bonferroni multiple-testing correction thresholds (Zuk et al.,
2014). Nonetheless, failure to meet the stringent Bonferroni
threshold does not preclude the possibility of interesting and
relevant results, especially when combined with other functional
evidence, which is what we have sought to do to increase con-
fidence in our findings. This challenge has been similarly docu-
mented in other heterogeneous disorders such as autism
(Yuen et al., 2015; C Yuen et al., 2017) and schizophrenia (Singh
et al., 2017), where single genes with a burden of rare damaging
variants in cases compared to controls have also not attained
the required statistical burden of proof. Nonetheless, the results
of those studies have provided important insights into the ge-
netic etiology of those disorders. Namely, in the schizophrenia
study, Singh and colleagues demonstrated that a group of
3,488 genes previously shown to be intolerant to LOF mutations
were enrichedwith a burden of rare deleterious variants in cases,
identifying this group of genes as a whole as important in
schizophrenia.
This result is analogous to our gene set analyses findings.
We provide for the first time evidence that a group of 157
genes mapping nearest to BMI-associated GWAS loci are en-
riched in very rare deleterious variants in our cases. Further-
more, we demonstrate that a subset of 53 out of those 157
genes (that have evidence of being LOF intolerant genes) is
even more enriched in very rare functional variants in obese
cases, compared to controls achieving effect estimates
similar in size to the group of well-established monogenic
obesity genes. This set of 53 genes is therefore a primary
target to study in more detail in future large-scale obesity
sequencing studies.
Last, we demonstrate that collectively the 3,488 genes
intolerant to LOF (pLi > 0.9-set) are enriched in very rare pre-
dicted deleterious variants in severe early-onset obese pa-
tients who also have developmental delay, suggesting that
further novel discoveries that are clinically relevant may be
made by studying this particular subgroup of individuals
and genes.
Limitations of Study
Our study hasanumberof limitations. First, all the newlydescribed
genes linked to childhood obesity are driven mostly from our dis-1116 Cell Metabolism 31, 1107–1119, June 2, 2020covery dataset and, aside from ZMYM4, neither PHIP nor DGKI
meet Bonferroni correction for all genes in the genome. Conse-
quently, thesefindingsmerit replication inadditional caseswithse-
vere childhood-onset obesity and also in adult obesity cases and
other ancestries, to further investigate the impact of these genes
in obesity more broadly. Second, while we observe enrichment
ofvery rarepredicteddeleteriousvariants inPHIP, incaseswithse-
vere childhoodobesity in the absenceof developmental delay, this
observation merits additional investigation in additional obesity
cases (with and without developmental delay) to identify possible
genotype-phenotype correlations. Third, theDGKImouse exhibits
increased fat mass only inmales; further work is therefore needed
to evaluate the apparent gender dimorphism, and to gain insights
into themechanism underlying the effect on body composition we
observe. Overall, our results highlight the challenges in robustly
linking very rare variantswith incomplete penetrance to a complex
and heterogeneous phenotype such as obesity.
To conclude, we demonstrate that WES in clinically ascer-
tained severe-childhood onset obesity, and follow-up in addi-
tional unrelated cases, identifies genes and gene sets newly
linked to obesity. Further investigation of the molecular mecha-
nisms affected by rare obesity-associated variants in cells,
model organisms, and humans may identify and validate poten-
tial targets for weight loss therapy.STAR+METHODS
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Rabbit anti-PHIP Proteintech Cat # 20933-1-AP; RRID: AB_10733522
Goat anti rabbit secondary antibody Alexa
Fluor 488
Thermo Fisher Scientific Cat# A11034; RRID: AB_2576217
Mouse anti-HA tag (6E2) Cell Signaling Cat# 2367; RRID: AB_10691311
Normal Rabbit IgG Cell Signaling Cat# 2729; RRID: AB_1031062
Rabbit anti-IRS2 (L1326) Cell Signaling Cat# 3089; RRID: AB_2125771
Rabbit anti-PHIP Abcam Cat# ab86244; RRID: AB_1925318
Goat anti-rabbit IgG-HRP Dako Cat# P0448; RRID: AB_2617138
Rabbit anti-p44/42 MAPK (Erk1/2) (137F5) Cell Signaling Technology Cat# 4695; RRID: AB_390779
Rabbit anti-Phospho-p44/42 MAPK
(Erk1/2) (Thr202/Tyr204)
Cell Signaling Technology Cat# 9101; RRID: AB_331646
Rabbit anti-STAT3 Cell Signaling Technology Cat# 4904; RRID: AB_331269
Rabbit anti-Phospho STAT3 (pY705) Cell Signaling Technology Cat# 9131; RRID: AB_331586
Rabbit anti-bActin Cell Signaling Technology Cat# 4967; RRID: AB_330288
Bacterial and Virus Strains
XL10-Gold Agilent Cat# 200315
Chemicals, Peptides, and Recombinant Proteins
Lipofectamine 2000 GIBCO Cat#11668
Formaldehyde Fisher Chemicals F/150/PB17
Triton X-100 BDH 306324N
Human Recombinant E.coli Leptin EMD Millipore 429700
Protein A Sepharose Abcam ab193256
DAPI Invitrogen D1306
Critical Commercial Assays
Steadylite Plus Reporter Gene Assay
System
Perkin Elmer 6066759
Sample-to-SNP kit ThermoFisher 4403081
Experimental Models: Cell Lines
HEK293 ATCC CRL-1573; RRID: CVCL_0045
COS7 culture collection by Alan Tunnacliffe N/A
Experimental Models: Organisms/Strains
Dgki (EM:11471), Zmym4 (EM:11435) and
Znf32/Zfp637 (EM:11616)
Infrafrontier (https://www.infrafrontier.eu/)
or they can be obtained from WSI directly:
mouseinterest@sanger.ac.uk
EM:11471, EM:11435, EM:11616
Recombinant DNA
Human N-HA-PHIP-WT in pCDNA3.1(+)
vector
This paper N/A
Human N-HA-PHIP variants in
pCDNA3.1(+) vector
This paper N/A
Software and Algorithms
Prism 7 Graph Pad Software https://www.graphpad.com/scientific-
software/prism/
WGE CRISPR tool (Hodgkins et al., 2015) N/A
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GATK Haplotype Caller (v3.2) (DePristo et al., 2011; Van der Auwera
et al., 2013)
https://github.com/broadinstitute/gatk/
releases
VerifyBamID (v1.0) (Jun et al., 2012) https://genome.sph.umich.edu/wiki/
VerifyBamID
EIGENSTRAT v4.2 (Price et al., 2006) https://www.hsph.harvard.edu/alkes-
price/software/
Meta, R package v4.9 (Balduzzi et al., 2019) N/A
PhenStat, R package version 2.18.0 (Kurbatova et al., 2015) Available from Bioconductor (Gentleman
et al., 2004)
PLINK (Purcell et al., 2007) http://zzz.bwh.harvard.edu/plink/
PLINK/SEQ N/A https://atgu.mgh.harvard.edu/plinkseq/
index.shtml
ProxECAT (Hendricks et al., 2018) N/A
SNPtest v2.5 (Marchini and Howie, 2010) https://mathgen.stats.ox.ac.uk/
genetics_software/snptest/snptest.html
Variant Effect Predictor (VEP) version 79
with the dbNSFP plug-in (dbNSFPv2.9, Feb
3, 2015
(McLaren et al., 2016; Liu et al., 2011, 2013) http://www.ensembl.org/vep; https://sites.
google.com/site/jpopgen/dbNSFP
SKAT, R package version 1.1 (Lee et al., 2012) Available from CRAN (https://cran.r-
project.org/web/packages/SKAT/
index.html)
MetaSKAT, R package version 0.60 (Lee et al., 2013) Available from CRAN (https://cran.r-
project.org/web/packages/MetaSKAT/
index.html)
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Lead Contact
Further information and requests for reagents may be directed to and will be fulfilled by the Lead Contact, Ineˆs Barroso (ines.
barroso@exeter.ac.uk).
Materials Availability
Plasmids generated in this study are available from the lead contact. Mouse lines generated in this study will be available from In-
frafrontier (https://www.infrafrontier.eu/) or they can be obtained from WSI directly, mouseinterest@sanger.ac.uk. Dgki
(EM:11471), Zmym4 (EM:11435) and Znf32/Zfp637 (EM:11616). There are currently some restrictions to the availability of mouse lines
from Infrafrontier due to the patent issues surrounding CRISPR-generatedmice, however these restrictions are being resolved and in
the interim mouse lines are available directly from Wellcome Sanger Institute by contacting mouseinterest@sanger.ac.uk.
Data and Code Availability
SCOOPand INTERVALWESdata are accessible from the EuropeanGenome-phenome Archive- EGA: EGAS00001000124 and EGA:
EGAS00001000825, respectively. Adult obesity WES data from UK10K Generation Scotland and TwinsUK are available from EGA
under accession codes EGA: EGAS00001000242 and EGA: EGAS00001000306, respectively. 1958 Birth Cohort WES data is avail-
able from the EGA under accession code EGA: EGAS00001000971. All other data are available in the manuscript or the supplemen-
tary materials.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human Studies
All studies were approved by the Cambridge Local Research Ethics Committees and all participants and their parents (for children
below the age of 16) gave written informed consent. All research was conducted in line with the principles outlined in the Declaration
of Helsinki.
Samples
Stage 1 used whole-exome sequence data from participants in the SCOOP and INTERVAL studies (details below). Stage 2 included
targeted sequence and genotype data obtained for additional SCOOP participants and participants from the FENLAND study (detailsCell Metabolism 31, 1107–1119.e1–e12, June 2, 2020 e2
ll
OPEN ACCESS Articlebelow). Whole-exome sequence adult obesity data was obtained for adult obesity participants in the UK10K project (Walter et al.,
2015) and 1958 Birth Cohort participants were used as controls, but only data for four genes surviving combined stage1+stage2 anal-
ysis were analyzed.
Childhood Obesity Cases
The Severe Childhood Onset Obesity Project (SCOOP) cohort (Wheeler et al., 2013), includes 4800 British individuals of European
ancestry with childhood onset obesity (BMI standard deviation score (SDS) > 3; onset of obesity before the age of 10 years). SCOOP
individuals likely to have congenital leptin deficiency, a treatable cause of severe obesity, were excluded by measurement of serum
leptin, and individuals with mutations in the melanocortin 4 receptor gene (MC4R) (the most common genetic form of penetrant
obesity) were excluded by prior Sanger sequencing. All participants had age < 10y at the time of recruitment, sex distribution
was: Female 548 (59.12%), Male 379 (40.88%).
In this study, SCOOP participants were included in stage 1 and stage 2 analyses. Stage 1 analysis comprised 982 SCOOP indi-
viduals with whole-exome sequence (WES) data obtained as part of the UK10K consortium project (Walter et al., 2015; Hendricks
et al., 2017). WES sequence data can be obtained from the European Genome-phenome Archive (EGA) under study accession
code EGAS00001000124 (Walter et al., 2015; Hendricks et al., 2017). Stage 2 analyses included 1,816 SCOOP participants selected
from a total of 2,819 participants with existing sequence data on1,300 genes (Walter et al., 2015). Selection of stage 2 samples was
based on: i) presence of good quality sequence data (proxy for good quality DNA); ii) European ancestry as defined by principal
component analysis on off-target variants (LASER 2.0 algorithm (Wang et al., 2015) and; iii) unrelated to SCOOP stage 1 samples.
All participants had age < 10y at the time of recruitment, sex distribution was: Female 951 (52.37%), Male 865 (47.63%).
Adult Obesity Cases
WES data obtained as part of the UK10K consortium project (Walter et al., 2015) was available for 366 Generation Scotland and 65
TwinsUK unrelated participants with BMI > 40, and good quality sequence data. These data are available from EGA under accession
codes EGA: EGAS00001000242 and EGA: EGAS00001000306. All TwinsUK participants were female, but age information was not
available to us at the time of analysis. Age and sex of GS samples were not available to us at the time of analysis. The effect of age and
sexwas not considered in this study as our discovery study design did not allow us to investigate these parameters due to both power
issues (low power for stratified analysis), and the fact that the discovery phase contrasted obese prepubertal children with age < 10y
at recruitment with control adults.
Population Controls
Stage 1 analysis included 4,502 participants from the INTERVAL cohort. The INTERVAL cohort consists of 50,000 predominantly
healthy blood donors in the UK (Moore et al., 2014). All individuals were genotyped using the UK Biobank Axiom Array (Affymetrix
Axiom Biobank Array) and imputed using a combined UK10K-1000G Phase 3 imputation panel (Huang et al., 2015). A subset of
4,502 individuals were selected for whole-exome sequencing, as previously described (Singh et al., 2016), of which 4,499 survived
QC and were used as controls in this study. Information on age and sex was available to us for 4,045 of the 4,057 participants
(99.70%): Age mean (SD): 43.51 (14.31); Sex Female 1,994 (49.30%), Male 2,051 (50.70%). Further details on the INTERVAL study
can be obtained at https://www.intervalstudy.org.uk/.
Stage 2 analysis included participants from Phase 1 of the Fenland Study. The Fenland Study is a population-based cohort of
12,435 participants born between 1950 and 1975, recruited from participating General Practices from around the Cambridgeshire
region in the UK. Exclusion criteria were: clinically diagnosed diabetes mellitus, inability to walk unaided, terminal illness (life expec-
tancy ofG1 year at the time of recruitment), clinically diagnosed psychotic disorder, pregnancy or lactation (Clifton et al., 2017). Par-
ticipants were aged 29-64 years and 53.8% were female. For the stage 2 genotyping (see below) we used 3,800 randomly selected
Fenland Study participants (age range 29-64, of which sex information was available to us for 3,777 that passed QC: Female 2,040
(54.01%),Male 1,737 (45.99%)), of which a subset of 2,660 (age range 29-64, of which sexwas available to us for 2,627: Female 1,392
(52.99%), Male 1,235 (47.01%)) was randomly selected for the stage 2 targeted gene sequencing (see below). Further details on the
Fenland Study, including a technical summary, can be found here: http://www.mrc-epid.cam.ac.uk/research/studies/fenland/
Association analysis with adult obesity used 1,000 participants from the 1958 Birth Cohort as controls. The 1958 Birth Cohort
Collection is a population-based collection of all individuals born in a week in 1958 in the UK (http://www.cls.ioe.ac.uk). Whole-
exome data were obtained from EGA under accession code EGA: EGAS00001000971. Age and sex information of participants
included in this study was not available at the time of analysis and was not considered in this study as our discovery study design
did not allow us to investigate these parameters due to both power issues (low power for stratified analysis), and the fact that the
discovery phase contrasted obese prepubertal children with age < 10y at recruitment with control adults. Briefly, genomic DNA
was used to prepare DNA libraries using the Illumina TruSeq sample preparation kit. DNA was fragmented using Covaris technology
and libraries were prepared without gel size selection. Target enrichment was performed in pools of six libraries using the Illumina
TruSeq Exome Enrichment kit. Captured DNA libraries were PCR amplified using the supplied paired-end PCR primers. Sequencing
was performed with an Illumina HiSeq2000 (v3 flow cell, one pool per lane) generating 2x100-bp reads (Loveday et al., 2015).
gnomAD controls were the non-Finnish control exome samples (N = 21,384). GnomAD v2.1 data was downloaded on October 12,
2018 from https://gnomad.broadinstitute.org/downloadse3 Cell Metabolism 31, 1107–1119.e1–e12, June 2, 2020
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Animals, Housing and Husbandry
All mice were maintained in specific pathogen-free facilities in individually ventilated cages at standard temperature (19-23C) and
humidity (55% ± 10%), on a 12 h dark, 12 h light cycle (lights on 0730–190) and fed a breeder’s chow diet (LabDiet 5021-3, 9% crude
fat content, 21% kcal as fat, 0.276ppm cholesterol, LabDiet, London, UK).
All mice were given water and diet ad libitum, unless otherwise stated. Mice were maintained in a specific pathogen free unit on a
12 h light: 12 h dark cycle with lights off at 7:30pmand no twilight period. The ambient temperaturewas 21 ± 2Cand the humidity was
55 ± 10%.Mice were typically housed for phenotyping using a stocking density of 3-5mice per cage (overall dimensions of caging: (L
x W x H) 3653 2073 140mm, floor area 530cm2) in individually ventilated caging (Tecniplast Seal Safe Plus GM500) receiving 60 air
changes per h. In addition to Aspen bedding substrate, standard environmental enrichment of two nestlets, a cardboard tunnel and
three wooden chew blocks was provided. Mice stocking density was typically 3-5 mice per cage. The care and use of mice was per-
formed in accordance with UK Home Office regulations, UK Animals (Scientific Procedures) Act of 1986 under a UK Home Office
license (P77453634) and which were reviewed regularly by the WTSI Animal Welfare and Ethical Review Body. Animal welfare
was assessed routinely for all mice involved. Mouse lines for the genes used in this study [Dgki (EM:11471), Zmym4 (EM:11435)
and Znf32/Zfp637 (EM:11616)] can be ordered from Infrafrontier (https://www.infrafrontier.eu/).
Generation of Dgkiem1(IMPC)Wtsi Mutant Mice
C57BL/6N mouse zygotes were injected cytoplasmically with Cas9 mRNA (50ng/ml) from Trilink Biotechnologies and two pairs of
in vitro transcribed gRNAs (6.25ng/ml each) flanking a critical exon. gRNAs were identified using the WGE CRISPR tool (Hodgkins
et al., 2015) and were selected based on their off-target scores to minimize potential off target damage.Sequence Chromosome Chromosome Start Chromosome End
GCACTGATCCAACAATTTGGTGG 6 37049961 37049983
ATATTATGGCCATATTACGGAGG 6 37050131 37050153
CCTGTAGACTGTCCCAAATCCAT 6 37050402 37050424
CCTGAGTAGTTCCATTAGACTTA 6 37050669 37050691The zygotes were transferred into the oviduct of pseudopregnant females the same day of microinjection. G0 founder mosaic
offspring were identified using a combination of end point PCR and gene-specific ‘loss of WT allele’ (LoA) qPCR assay designed
to the region of the genome predicted to be deleted. G0 founder mice were mated to C57BL/6N mice to establish G1’s for further
breeding to C57BL/6N mice. Genomic DNA from pups produced by cytoplasmic injection of CRISPR/Cas9 reagents was isolated
from an ear punch of two week old pups using the Sample-to-SNP kit (ThermoFisher, 4403081).
Endpoint PCR Primer Pairs and Expected Size BandsAssay type Assay Forward Primer Reverse Primer Expected Size Band (bp)
Standard PCR Wild type Dgki_DF1 Dgki_ER1 363
Standard PCR Wild type Dgki_EF1 Dgki_DR1 566
Standard PCR Mutant Dgki_DF1 Dgki_DR1 286
Primer Name Primer Sequence (50 > 30)
Dgki_DF1 GTCTCCAAAATCAGACACGCA
Dgki_EF1 ACAAAAGGCATTTTTCCCACC
Dgki_ER1 GGTACCTGAATCCACGGCAALoA qPCR Primers
Dgki_DR1 ATGACATAGCCTGGCCACTTTarget Forward Primer Seq. Reverse Primer Seq. Probe Primer Seq.
Dgki AGATCAAAGACTTGCCGTGGAT CCTTTATAGGGAACCAAAGTCCTACA CAGGTACCACATAAACViability of the line is assessed by genotyping a minimum of 28 offspring from heterozygous intercrosses. For Dgkiem1(IMPC)Wtsi, this
gave 23 homozygous mice from 95 offspring (Expected: 24 from 95 offspring, Fisher- exact test, p = 1.0). Mice were allocated to the
pipeline randomly by Mendelian Inheritance.Cell Metabolism 31, 1107–1119.e1–e12, June 2, 2020 e4
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C57BL/6N mouse zygotes were injected cytoplasmically with Cas9 mRNA (50ng/ml) from Trilink Biotechnologies and in vitro tran-
scribed gRNAs (6.25ng/ml each) flanking a critical exon. gRNAs were identified using the WGE CRISPR tool (Hodgkins et al.,
2015) and were selected based on their off-target scores to minimize potential off target damage.Sequence Chromosome Chromosome Start Chromosome End
CCACTATTCGGCTAAAAGATGCA 4 126910579 126910601
CGTAATGCATGTACAGAAACTGG 4 126910605 126910627
CCACCCTCTTGGTATATTAAAGG 4 126911331 126911353The zygotes were transferred into the oviduct of pseudopregnant females the same day of microinjection. G0 founder mosaic
offspring were identified using a combination of end point PCR and gene-specific ‘loss of WT allele’ (LoA) qPCR assay designed
to the region of the genome predicted to be deleted. G0 founder mice were mated to C57BL/6N mice to establish G1’s for further
breeding to C57BL/6NTacmice. Genomic DNA frompups produced by cytoplasmic injection of CRISPR/Cas9 reagents was isolated
from an ear punch of two week old pups using the Sample-to-SNP kit (ThermoFisher, 4403081).
Endpoint PCR Primer Pairs and Expected Size BandsAssay type Assay Forward Primer Reverse Primer Expected Size Band (bp)
Standard PCR Wild type Zmym4_DF1 Zmym4_ER1 274
Standard PCR Wild type Zmym4_EF1 Zmym4_DR1 531
Standard PCR Mutant Zmym4_DF1 Zmym4_DR1 98
Primer Name Primer Sequence (50 > 30)
Zmym4_DF1 CCACCACCCAGCCTAAAAGA
Zmym4_EF1 CCCCCACAGTTCTCACAACA
Zmym4_ER1 TCAGGGGAGTTGAAACCTTGGLoA qPCR Primers
Zmym4_DR1 GGTGCTCTTACCCACTGAGCTarget Forward Primer Seq. Reverse Primer Seq. Probe Primer Seq.
Zmym4 TGAGGTGACACACATTGAACTACAA CAGTGCCATGTGCTGCAAAT ACTTCTTAGACTGCCCCTCViability of the line is assessed by genotyping a minimum of 28 offspring from heterozygous intercrosses. For Zmym4em1(IMPC)Wtsi
this gave 0 homozygous mice from 56 offspring (Expected: 14 from 56 offspring, Fisher- exact test, p < 0.0001).
Primary Standardized Phenotyping Pipeline
Mice underwent primary standardized phenotyping from 4 weeks of age and had only previously undergone earclip biopsies to iden-
tify the mice and establish genotype before entering the pipeline. Mice were randomly assigned to cohorts by Mendelian inheritance
by colony managers that were separate from the team performing the phenotyping. Dgki homozygous mutant mice on the C57BL/
6NTac background were tested in 7 batches (2 batches of 2 females each, 1 batch of 1male, 1 batch of 1 female, 1 batch of 2 females
and 1 male, 1 batch of 2 males and 1 batch of 3 males). All 14 Dgkimutant mice completed the pipeline without loss due to welfare or
health concerns. No health concerns or adverse effects were noted during or outside of procedures. With each batch of mutant mice,
a cohort of typically 7 age and sex matched (though not littermate) wild-type C57BL/6NTac mice were also phenotyped, to provide
longitudinal control values as described in the Quantification and Statistical Analysis section. Key phenotyping results are shown in
Figures S6 and S7. Data collected include weight curves, basic behavioral/morphological assessment at 9 weeks of age, intraper-
itoneal glucose tolerance test (ipGTT) at 13 weeks and body composition assessment by dual emission X-ray absorptiometry (DEXA)
at 14 weeks of age using a modified version of the MGP pipeline detailed previously (White et al., 2013), using a mouse breeder’s
chow (LabDiets 5021, 9% crude fat content, 21% kcal as fat, 0.276ppm cholesterol, LabDiet, London, UK) instead of a high fat
diet. At 16 weeks, random-fed mice were anesthetized using 100 mg/kg Ketamine and 10 mg/kg Xylazine and blood was collected
retroorbitally. Samples were used to measure total blood counts, clinical chemistry parameters and for analysis by flow cytometry.
Death was confirmed by cervical dislocation and heart removal. As a high throughput screen where genes are selected for study
without hypothesis and mice are studied in multiple batches and alongside mice with mutations for different genes, there is limitede5 Cell Metabolism 31, 1107–1119.e1–e12, June 2, 2020
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tion and hence the intraperitoneal glucose tolerance test (ipGTT) and Dual-energy X-ray absorptiometry (DEXA) screens are run un-
blinded. Basic behavioral/morphological assessments were runwith the technician blinded to the specific allele of themouse, but not
whether themouse was wild type or amutant. Necropsies of mice were performed by staff blinded to genotype and allele. Analysis of
blood samples for clinical chemistry were run blind using a barcode system. Typically, necropsies and blood collections are per-
formed from 9am-12pm, fasting for GTT starts 9amwith the sample collection beginning at 1pm. DEXA and behavioral analysis could
be performed at any time between 9am and 4pm. The order of cages andmice treated and assessed in any given procedure was not
predetermined. All data was collected using a bespoke mouse and data management system to allow QC of data under predefined
conditions, and data was only analyzed once all data from that line had been collected. The standard operating procedures can be
found at IMPReSS (https://www.mousephenotype.org/impress).
Dual-energy X-ray absorptiometry: DEXA was performed using an Ultrafocus 100 (Faxitron Bioptics LLC, Tuscon, Arizona, USA)
under isofluorane anesthesia (IsoFlo, Zoetis UK Ltd., London, UK), in order to minimize recovery times while immobilizing the mouse
for data collection. Nose to tail base length measurements were performed using a ruler with 1mm graduations prior to DEXA mea-
surement. Parameters measured included fat mass (g), fat percentage estimate (%), lean mass (g), bone mineral density (mg/cm2),
and bone mineral content (g). Internal calibration was performed prior to any imaging.
Intraperitoneal Glucose tolerance test: Mice were single-housed and fasted for 4 h. Approximately 0.5mm of the tail tip was
removed with a scalpel blade and a fasting blood sample (T0) was directly taken (Accu-chek Aviva, Roche, Indianapolis, IN). Mice
were then injected with 2g/kg glucose intraperitoneally and further blood samples were taken at 15 (T15), 30 (T30), 60 (T60) and
120 (T120) minutes post-glucose injection. Area under the curve (AUC) was calculated using the trapezoid method, where glucose
at T0 was used as the baseline value for the mouse. Two female and onemale homozygousmice had their T15 to T120 data removed
from analysis due to glucose injection failures.
Clinical Chemistry (CC): Blood was collected from animals in the random-fed state between 08:30 and 10:30. Mice were anesthe-
tized using 100mg/kg Ketamine and 10mg/kg Xylazine and blood was collected into heparinized pediatric tubes (Kabe Labortechnik
GmbH, Numbrecht, Germany) using the retro-orbital route, followed by heart removal and cervical dislocation. This anesthesia/
administration combination allowed the collection of a sufficient amount of non-hemolyzed blood, particularly for electrolyte param-
eters that may be strongly affected by hemolysis. Heparinized whole-blood samples were centrifuged at 5,000 rcf for 10 min at 4C,
and the plasma was collected and stored at 4C until analysis, always within 1 h of collection. Plasma variables were assessed at
room temperature using an AU480 chemistry analyzer (Beckman Coulter, High Wycombe, UK). Glucose levels were not analyzed
from the clinical chemistry screen due to the rapid increase in plasma glucose under Ketamine/Xylazine based anesthesia.
METHOD DETAILS
Cell Culture
HEK293 (XX female) cells were cultured in high glucose Dulbecco’s modified eagle medium (DMEM, GIBCO, 41965) supplemented
with 10% fetal bovine serum (GIBCO, 10270, South America origin), 1% GlutaMAX (100X) (GIBCO, 35050), and 100 units/mL peni-
cillin and 100 mg/mL streptomycin (Sigma-Aldrich, P0781) at 37C, 5%CO2. COS-7 (XYmale) cells were cultured in low glucose Dul-
becco’s modified Eagle’s medium (Sigma, D6046) supplemented with 10% fetal bovine serum, 1% GlutaMAX, 100 IU/mL penicillin
and 100 ng/mL streptomycin at 37C, 5% CO2.
Cloning of PHIP Human Variants
PHIP cDNA constructs containing an N-terminal HA tag in pCDNA3.1 (+) vector (Invitrogen) were used throughout the study
(NM_017934.7). Site-directed mutagenesis was performed using Q5 site-directed mutagenesis kit (NEB, E0554S) according to
the manufacturer’s protocols. All constructs were verified with Sanger sequencing.
Subcellular Localization of Endogenous PHIP
COS-7 cells were seeded in black clear bottom CellCarrier-96 Ultra Microplates (Perkin Elmer, 6055302) coated with Poly-D-Lysine
solution (Sigma, A-003-E) (20.000 cells/well). After 24 h, cells were fixed with 4% Formaldehyde (Fisher Chemicals, F/150/PB17) in
Phosphate-buffered saline (PBS) for 20min at room temperature, permeabilized with 0.2%Triton X-100 (BDH, 306324N) for 30min at
room temperature, blocked for 1 h in 3% Bovine Serum Albumine (BSA) (Sigma, A7906) at room temperature, and incubated over-
night at 4C with Rabbit anti-PHIP (Proteintech, 20933-1-AP) in 1:100 dilution in 3% BSA or without antibody as a negative control.
Cells were washed three timeswith PBS for 5min, incubatedwith goat anti rabbit secondary antibody Alexa Fluor 488 (Thermo Fisher
Scientific, A11034) in 1:200 dilution in 3% BSA for 1 h at room temperature, washed 2 times with PBS for 5 min, incubated with DAPI
(Invitrogen, D1306) in 1:500 dilution in PBS for 10 min and kept in PBS. Cells were imaged in the Opera Phenix High Content
Screening Confocal system (Perkin Elmer).
Luciferase POMC Transcription Activation Assay
HEK293 cells were seeded into white 96-well plates coatedwith Poly-D-Lysine (40,000 cells/well) and transiently transfected the next
day with 100ng/well plasmid encoding either empty pcDNA3.1(+) vector (negative control), WT or mutant PHIP plasmid, combined
with 50ng/well plasmid for Leptin Receptor, 50ng/well plasmid for POMC luciferase and 10ng/well plasmid for STAT3 usingCell Metabolism 31, 1107–1119.e1–e12, June 2, 2020 e6
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ufacturer’s protocols. After 6 h transfection media was replaced by full DMEM. The next day cells were incubated overnight with star-
vation media (DMEM no FBS) with or without the presence of 200ng/mL Leptin (Human Recombinant E.coli, EMDMillipore, 429700).
Quantitation of firefly luciferase activity was performed using the Steadylite Plus Reporter Gene Assay System (Perkin Elmer,
6066759) according to the manufacturer’s protocol.
Dominant Negative Luciferase POMC Transcription Activation Assay
HEK293 cells were seeded in white 96-well plates coated with Poly-D-Lysine (40,000 cells/well) and transiently transfected the next
day with 50ng/well plasmid encoding empty pcDNA3.1(+) vector together with 50ng/well WT PHIP plasmid or 50ng/well WT PHIP
plasmid together with different concentrations of mutant PHIP plasmid and combined with 50ng/well plasmid for Leptin Receptor,
50ng/well plasmid for POMC luciferase and 10ng/well plasmid for STAT3 using Lipofectamine 2000 in Opti-MEM Imedium according
to the manufacturer’s protocols. After 6 h, transfection media was replaced by full DMEM. The next day cells were incubated over-
night with starvation media (DMEM no FBS) with or without the presence of 200ng/mL Leptin. Quantitation of firefly luciferase activity
was performed using the Steadylite Plus Reporter Gene Assay System (Perkin Elmer, 6066759) according to the manufacturer’s
protocol.
Subcellular Localization of Human PHIP Variants
COS-7 cells were seeded into black clear bottom CellCarrier-96 Ultra Microplates coated with Poly-D-Lysine (20.000 cells/well) or
into glass coverslips in 12-well plates coated with Poly-D-Lysine (150.000 cells/well). Cells were transiently transfected with 100ng/
well plasmid encoding either empty pcDNA3.1(+) vector (negative control), WT or mutant PHIP plasmid, combined with 50ng/well
plasmid for Leptin Receptor, and 10ng/well plasmid for STAT3 using Lipofectamine 2000 in Opti-MEM I medium according to the
manufacturer’s protocols. After 6 h, transfection media was replaced by full DMEM. The next day cells were incubated overnight
with starvation media and stimulated with 200ng/mL Leptin for 10 min. Cells were immediately fixed with 4% Formaldehyde in
PBS for 20 min at room temperature, permeabilized with 0.2% Triton X-100 for 30 min at room temperature, blocked for 1 h in
3% BSA at room temperature and incubated overnight at 4C with Mouse anti-HA tag (6E2) (Cell Signaling, 2367) in 1:100 dilution
in 3% BSA. Cells were washed three times with PBS for 5 min, incubated with goat anti mouse secondary antibody Alexa Fluor
488 in 1:200 dilution in 3%BSA for 1 h at room temperature, washed 2 times with PBS for 5min, incubated with DAPI in 1:500 dilution
in PBS for 10 min and kept in PBS. Cells in the 96 well plates were imaged in the Opera Phenix High Content Screening Confocal
system, obtaining 9 images per well. Quantification of nuclear and cytoplasmic localization was performed with the Harmony soft-
ware (Perkin Elmer) using the Alexa 488 signal and nucleus to cytoplasm ratio was calculated by dividing the number of cells/well with
positive signal in the nucleus (normalized to total number of cells in the well) to the number of cells/well with positive signal in the
cytoplasm (normalized to total number of cells in the well). Slides were imaged using a Leica SP8 confocal microscope (Leica Micro-
systems). In both experiments images were processed using FIJI.
In Vitro Immunoprecipitation Assay
HEK293 cells stably expressing the leptin receptor were seeded in 10cm cell culture dishes coatedwith Poly-D-Lysine (500.000 cells/
well). Cells were starved overnight, stimulated with 200ng/mL insulin (Sigma, i9278) or leptin for 15 min and lysed with cell lysis buffer
containing 50 mM Tris, 50 mM KCL, 10 mM EDTA, 1% NP-40, supplied with protease inhibitor cocktail (Roche cOmplete, Mini Pro-
tease Inhibitor Cocktail, 11836153001) and phosphatase inhibitor cocktail A (Roche PhosSTOP, PHOSS-RO). Samples were soni-
cated 30seconds on/60 s off for 4 times at 4C using the Diagenode Bioruptor+ (Diagenode) and collected by centrifugation at
14000 rpm for 20min at 4oC. An aliquot was kept as input and the rest was aliquoted in comparable amounts of protein (1mg/sample)
and incubated with 20ml per sample of Protein Beads A (Protein A Sepharose, Abcam, ab193256) for 2 h at 4C (pre-clean up). Sam-
ples were span at 800rpm for 30 s and incubated overnight with 5ml of normal Rabbit IgG (Cell Signaling, 2729) or Rabbit anti-IRS2
(L1326) (Cell Signaling, 3089). The next day Protein Beads A were blocked with 5% BSA and 1%NP40 for 2 h at 4C, incubated with
the sample and antibody mix for 3 h at 4C and washed 4 times with Tris-buffered saline (TBS) supplemented with 0.1% Tween 20
(TBS-T) at room temperature. Beads were eluted in 20ml PBS, 3ml Bolt reducing agent (Thermo, B0009) and 7ml Bolt LDS sample
buffer (Thermo, B0007) for 10 min at room temperature followed by 10 min at 95C and final centrifugation for 2.5 min at
8000 rpm. For the input 20ml per sample were resuspended in Bolt LDS sample buffer and Bolt reducing agent and heated for
10 min at 95C. Equal volume of samples were loaded and protein electrophoresis was performed using Bolt 4%–12% Bis-Tris
Plus gels (Thermo, NW04125BOX) and transferred onto nitrocellulose membrane using an iBLOT (Thermo, IB301001). After blocking
with 5% milk solution in TBS-T for 1 h at room temperature, membranes were probed overnight at 4C using Rabbit anti-PHIP (Ab-
cam, ab86244) at 1:200 dilution in 5%milk in TBS-T. Cells were washed three times with TBS-T for 10 min at room temperature with
gentle shaking and incubated with secondary antibody, Goat anti-rabbit IgG-HRP (Dako, P0448) diluted 1:2000 in 5%milk in TBS-T
for 1 h at room temperature. Bands were developed using enhanced chemiluminescence (ECL) substrate (Promega, W1015) and
images were captured with an ImageQuant LAS 4000 (GE Healthcare). The band intensity of western blots was quantified using FIJI.
Western Blotting
HEK293 cells stably expressing the leptin receptor were seeded in 6 well plates coated with Poly-D-Lysine (50.000 cells/well). Cells
were starved overnight, stimulated with 200ng/mL leptin for indicated periods of time and lysed in radio-immunoprecipitation assaye7 Cell Metabolism 31, 1107–1119.e1–e12, June 2, 2020
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14.000 rpm for 30 min and prepared for electrophoresis as described previously. Membranes were blocked with 5% BSA solution
in TBS-T for 1 h at room temperature and probed overnight at 4C using Rabbit anti-p44/42 MAPK (Erk1/2) (137F5) at 1:1000 dilution
(Cell Signaling Technology, 4695), Rabbit anti-Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) at 1:1000 dilution (Cell Signaling
Technology, 9101), Rabbit anti-STAT3 at 1:1000 dilution (Cell Signaling Technology, 4904), Rabbit anti-Phospho STAT3 (pY705)
(Cell Signaling Technology, 9131) at 1:1000 dilution, Rabbit anti-PHIP at 1:1000 dilution (Proteintech, 20933-1-AP) and Rabbit
anti-bActin (Cell Signaling Technology, 4967) at 1:5000 dilution all prepared in the blocking buffer. Cells were washed three times
with TBS-T for 10 min at room temperature with gentle shaking and were incubated with secondary antibody, Goat anti-rabbit
IgG-HRP (Dako, P0448) diluted 1:2000 in 5% BSA in TBS-T for 1 h at room temperature. Bands were developed as described
previously.
QUANTIFICATION AND STATISTICAL ANALYSIS
Sequencing
All genetic data were on build GRCh37 coordinates.
Stage 1 Data
Stage 1 analysis included existing sequence data generated as part of other whole-exome sequencing efforts (details below).
Sequencing and Variant QC
Details of sequencing and variant calling for the SCOOP cases, as part of the UK10K exomes, and INTERVAL controls can be found
elsewhere (Hendricks et al., 2018; Walter et al., 2015; Singh et al., 2016). Briefly, single–sample variant calling using GATK Haplotype
Caller (v3.2) was performed on the union of Agilent v3 and v5 targets plus a 100 base pair flanking region on 9,795 UK10K and IN-
TERVAL samples, including SCOOP cases (N = 982) and INTERVAL controls (N = 4,499). The called variants were then merged into
200 sample batches and were joint-called using GenotypeVCFs and default settings (DePristo et al., 2011; Van der Auwera et al.,
2013). To ensure high-quality variant calls across all datasets and sequencing batches, only variants with at least 7x coverage in
at least 80% of samples were called. We applied further variant QC keeping only variants with a calibrated VQSR tranche above
99.75% sensitivity, missingness < 20%, Hardy-Weinberg equilibrium c2 p value > 10E-8, mean genotype qualityR 30, and variants
in low-complexity regions as described here (Li, 2014). Further, individual genotypes were set to missing if any of the following were
true: GQ < 30, alternate allele read depth (DP1)<2, allelic balance (AB, proportion of reads supporting one of the alleles of the geno-
type) < 0.2, or AB > 0.8.
Sample QC
We used VerifyBamID (v1.0) (Jun et al., 2012) and a threshold of R 3% to identify contaminated samples, principal components
calculated from the 1000Genomes Phase I integrated call set (Abecasis et al., 2010) using EIGENSTRAT v4.2 (Price et al., 2006)
to identify non-Europeans, and pairwise identity by descent estimates from PLINK v1.07 (Purcell et al., 2007) with a threshold of
R 0.125 to identify related individuals. We also removed samples with a mean read depth lower than 12. This process resulted in
927 SCOOP cases and 4,057 INTERVAL controls for stage 1 analysis. Among these 927 SCOOP cases, 226 were diagnosed with
developmental delay in addition to obesity.
Stage 2 Data
Stage 2 data included targeted sequencing data generated within this study and obtained from additional cases and controls, un-
related to stage 1 cases and controls.
Targeted Sequencing and Variant QC
Targeted sequencing was performed at the Wellcome Sanger Institute (WTSI). DNA samples (300ng), genomic (Fenland) or whole-
genome amplified (SCOOP), were pooled in up to 384 uniquely indexed paired-end libraries using the Illumina TruSeq Custom Am-
plicon Library Preparation Kit according to the manufacturer’s instructions, ensuring a mix of SCOOP and Fenland samples in each
384-well pool. Amplicons (in the range 220bp-280bp) were designed using Illumina’s tool DesignStudio, to cover exons, UTRs and
intron/exon boundaries of the 9 genes of interest, based on UCSC hg19. In total, 146 target regions were covered. Sequencing was
performed using 384-plexing and paired-end 300 cycles on Illumina MiSeq v2 to give bi-directional coverage of all amplicons.
Data were aligned to the 1000 Genomes Project Phase 2 GRCh37 human reference genome sequence (hs37d5). The CRAM files
produced from these alignments were converted to BAM format, removing duplicate flagging (SamTools v1.3 and BioBamBam2
v2.0.65). Variant calling was performed using Genome Analysis Toolkit (GATK) v3.6 HaplotypeCaller to call germline SNPs and indels
via local re-assembly of haplotypes, and GenotypeGVCFs to perform joint genotyping on all samples together. Variants were anno-
tated with the NCBI dbSNP database build 149, limiting to target regions ± 100bp.
Genotypes were set to missing if their depth was lower than 15, or if their genotype quality (GQ) was lower than 20 for SNPs and
lower than 60 for indels. For heterozygous genotypes, we further considered the allele balance (AB). Heterozygous genotypes with
AB outside of [15% - 85%] range were set to missing. Heterozygous genotypes with moderate AB in the ranges of [15% - 35%] or
[65%–85%] were required to have a depth greater than 25, otherwise the genotype was set to missing. Indels genotypes with depth
greater than 2000 were also set to missing.Cell Metabolism 31, 1107–1119.e1–e12, June 2, 2020 e8
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call rate was lower than 90%among cases or among controls; iii) difference in call rates between cases and controls was greater than
2.5%; iv) they failed anyGATK hard filtering (QualByDepth > 2 ; FisherStrand > 60 for SNPs or > 200 for indels ; RMSMappingQuality <
40 for SNPs or < 10 for indels; MappingQualityRankSumTest < 12.5; ReadPosRankSumTest < 8 for SNPs or < 20 for indels;
StrandOddsRatio > 3.0 for SNPs or > 10.0 for indels); v) window size for filtering adjacent gaps (GapWin) was lower than 3; vi) within
5bp around a gap to be filtered (SnpGap, for SNP). This process led to 858 variants of good quality in the 9 genes of interest.
Sample QC
Of the 1,816 SCOOP samples sequenced five had a missing rate greater than 15% and one had a mean depth below 12. Those six
samples were excluded, leaving 1,810 SCOOP cases for downstream analyses. Following the same process, 10 FENLAND samples
were excluded for having a missing rate greater than 15%, and three a mean depth below 12. This left 2,647 FENLAND controls for
stage 2 analysis.
Validation Sanger Sequencing
Sanger sequencing was performed to validate singleton and doubleton variants identified in stage 1 and stage 2 analyses from genes
with promising results (details below). Briefly, customized PCR primers were designed ± 250 bp surrounding the variant; sequencing
was performed using BigDye Terminator v3 kit (Applied BioSystems) and analyzed by capillary electrophoresis on an ABI3730 DNA
Analyzer platform (Applied Biosystems), according to the manufacturers’ instructions. Familial segregation analysis of variants was
performed where family samples were available and where family members consented to genetic studies. In total 42 singleton/
doubleton variants (48 genotypes) identified by LOF and STRICT analysis in stage 1 analysis were validated by Sanger sequencing
in the original cases and controls. All variants confirmed and all 9 genes were taken for stage 2 targeted sequencing. As targeted
sequencing was done on genome-amplified case DNA, 19 variants from cases from stage 2 analysis in four genes (DGKI, PHIP,
ZMYM4 and ZNF32) with promising stage 1+2 LOF and STRICT results (Table S6) were taken for sequence validation, of which
13 confirmed. Stage 2 variants seen in controls in the same four genes were also taken for validation: 9 variants were confirmed
and 1 doubleton variant was not (Table S6B). Final meta-analysis results of stage 1+ stage 2 validated variants are shown in Table
1.
Adult Obesity Cases and 1958BC Data
Although data were available exome-wide, we only performed lookup of data for four genes that had survived our combined
stage1+2 childhood obesity analysis.
Joint Calling, Sequencing and Variant QC
BAM files from the 1958 Birth Cohort and the Adult obesity cases were converted into gVCF format files using HaplotypeCaller
version 3.2-2-gec30cee of theGenomeAnalysis Toolkit (GATK) from the Broad Institute. The regions processed usingHaplotyeCaller
were restricted to the intersection of the Aigilent V3 and Illumina TruSeq baits, plus 100bp padding at both 30 and 50 ends of the baits.
The resulting gVCF files were combined in batches of 200 into multi-sample gVCF files using the GATK tool CombineGVCFs. These
multi-sample gVCFswere in turn further combined and variants called using theGATK tool GenotypeGVCFs so as to produce a single
VCF file containing the genotypes of all the samples included in the study. Quality scores for SNPs described in the VCF file were
improved by running GATK VariantRecalibrator, and subsequently applying these scores to the VCF file using GATK
ApplyRecalibration.
Variants were removed as part of the quality control process if: i) call rate was lower than 90%amongGeneration Scotland cases or
among TwinsUK cases or among controls; ii) difference in call rates in at least one of the three comparisons was greater than 2.5%
(Generation Scotland cases versus TwinsUK cases or Generation Scotland cases versus controls or TwinsUK cases versus controls);
iii) they failed any GATK hard filtering available (QualByDepth > 2 ; FisherStrand > 60 for SNPs or > 200 for indels ; RMSMapping-
Quality < 40 for SNPs or < 10 for indels; MappingQualityRankSumTest < 12.5; ReadPosRankSumTest < 8 for SNPs or < 20
for indels); iv) window size for filtering adjacent gaps (GapWin) was lower than 3; v) within 5bp around a gap to be filtered (SnpGap,
for SNP). This process led to 1,128,931 exome-wide variants of good quality.
Sample QC
Sample quality control was done across good quality variants. We identified one control sample with a missing rate greater than 5%;
13 control samples showing outlier relatedness values with most of the cases and controls, pointing to potential contamination; and
two control samples being non-European, based on the principal component analysis. No cases were further excluded. This left 431
adult obesity cases and 984 control samples for analysis.
Variant Annotation
Variant frequency was annotated with respect to the UK10K-cohort reference panel and each of the four global populations in the
1000 Genomes Phase 1 reference panel: African population (YRI, LWK, ASW), American population (MXL, CLM, PUR), Asian pop-
ulation (CHB, CHS, JPT) and European population (CEU, TSI, FIN, GBR, IBS). Variants were annotated for functional consequences
and damaging scores using the Ensembl Variant Effect Predictor (VEP) version 79 with the dbNSFP plug-in (dbNSFPv2.9, Feb 3,
2015) (McLaren et al., 2016; Liu et al., 2011, 2013). Allelic changes were defined as loss-of-function (LOF analysis, see below) if
the VEP consequence in protein-coding transcripts was among splice_donor_variant, splice_acceptor_variant, stop_gained, frame-
shift_variant. For allelic changes annotated as missense (VEP consequence in protein-coding transcripts), we further considered fivee9 Cell Metabolism 31, 1107–1119.e1–e12, June 2, 2020
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OPEN ACCESSArticletools available in dbNSFP to classify the change as damaging: SIFT prediction ‘‘damaging,’’ PolyPhen2 HDIV predictions ‘‘probably
damaging’’ and ‘‘possibly damaging,’’ PolyPhen2 HVAR predictions ‘‘probably damaging’’ and ‘‘possibly damaging,’’ LRT prediction
‘‘deleterious,’’ and MutationTaster prediction ‘‘disease causing automatic’’ or ‘‘disease causing.’’ Allelic changes were defined as
strictly damaging (STRICT analysis, see below) if the VEP consequence in protein-coding transcripts was LOF as defined above
or stop_lost or initiator_codon_variant or missense classified as damaging by all 5 prediction tools: this category aims to identify
allelic changes that are likely to be damaging. Allelic changes were defined as broadly damaging (BROAD analysis, see below) if
it was strictly damaging or missense classified as damaging by at least one of the 5 prediction tools: this category aims to discard
allelic changes that are likely to be benign.
Single-variant Association Analyses
Stage 1 and Stage 2 Analyses
Case-control association analysis was performed using SNPtest v2.5 with the -newml option, which implements a likelihood ratio
test. Analyses were done unadjusted for age and sex because of insufficient power for stratified analysis and, since all obese par-
ticipants were prepubertal with age < 10yr at recruitment, the study was not designed to address the effect of age or sex. In stage 1,
single-variant analysis was performed on all variants regardless of minor allele count (MAC) or imputation quality. Forty-seven var-
iants with p value < 104 and with case MAF > control MAF (Table S1), as well as an additional 14 variants driving gene-based an-
alyses (based on 10 genes fromBROAD analysis) were prioritized for stage 2 follow-up (Figure S1; Table S2C). After LD pruning using
PLINK (parameters:–clump-p1 0.0001–clump-p2 0.2–clump-r2 0.5–clump-kb 500), 53 variants remained. Of these, five variants
failed assay design resulting in 48 variants that were assayed on the stage 2 samples. Four SNPs were removed due to having a
call rate below 80% in either SCOOP cases or Fenland controls resulting in 44 SNPs for analysis in stage 2.
Stage1+2 Meta-Analysis
Fixed-effects meta-analysis, combining the original and replication samples, was performed using the R package Meta and function
metagen. No single variant passed single-variant genome-wide significance threshold (p value < 5x108) after meta-analysis (Ta-
ble S5).
Gene-based Association Analyses
Stage 1, Stage 2 and Adult Obesity versus Controls
Gene-based association analyses were performed using a nested approach considering three gene-burden tests filtering for variants
with different MAF and with different in silico variant function predictions. Analyses were done unadjusted for age and sex because of
insufficient power for stratified analysis and, since all obese participants were prepubertal with age < 10yr at recruitment, the study
was not designed to address the effect of age or sex.Manhattan andQQplots for the three gene-burden tests are shown in Figure S2.
The same approach was used in stage 1 (SCOOP versus INTERVAL, Table S2), stage 2 (SCOOP versus FENLAND, Table S6), and
adult obesity (Generation Scotland & TwinsUK versus 1958BC, Table S4).
Rare alleles were defined as alleles having a frequency lower than 1% in each of the four 1000G populations and in the UK10K-
Cohort reference panel, and also in at least one of the analysis groups. Namely, for stage 1 analysis, we required the alleles to be
rare (< 1%) across 4,057 INTERVAL control samples, or rare across the 927 SCOOP samples, or rare across the 431 adult obesity
cases. For stage 2, we required the allele to be rare (< 1%) across 2,647 FENLAND controls, or rare across 1,810 SCOOP samples.
For adult obesity versus 1958BC, we required the allele to be rare (< 1%) across 984 1958BC controls, or rare across 431 adult
obesity samples.
Similar to rare allele definition, very rare alleles were defined as alleles having a frequency lower than 0.025% in each of the four
1000G populations and in the UK10K-Cohort reference panel, and also in at least one of the analysis group. The MAF < 0.025%was
chosen to focus on variants likely to be private to any given family or clan, and avoid definitions based on ‘‘not seen in public data-
bases’’ which change over time.
We performed three nested gene-burden tests. 1- The LOF analysis considered variants with very rare alleles (MAF < 0.025%) for
which the change was categorized as being LOF as described above: 6,160 genes with at least 2 variants were analyzed. 2- The
STRICT analysis considered variants with very rare alleles (MAF < 0.025%) for which the variants were classified as having a dele-
terious effect by five in silico prediction programmes as described above: 13,496 genes with at least 2 variants were analyzed. 3- The
BROAD analysis considered variants with rare alleles (MAF < 1%) for which the change was categorized as broadly damaging as
described above: 17,885 genes with at least 2 variants were analyzed.
Gene-based analyses were performed using the SKATBinary function from the R package SKAT (version 1.1. 4, April 1, 2016) (Lee
et al., 2012). The p values were computed without adjustment (method.bin = ’’UA’’). LOF and STRICT analyses were performed using
the burden test implemented in SKATBinary (method = ’’Burden’’), while the BROAD analysis (rare and broadly damaging allelic
changes) was performed using SKAT-O (method = ’’SKATO’’). All other SKATBinary options were set to their default value. Stage
1 yielded seven genes based on LOF and STRICT analysis with OR > 1 and p value < 104 (Table S2), which were selected for stage
2 targeted sequencing. In addition, BROAD analysis yielded 10 genes with OR > 1 and p value < 104 (Table S2), of 10 genes, 8 genes
were driven by 12 variants based on leave-one-out analysis (see below) and 2 genes were influenced by 2 variants, but signal re-
mained after leave-one-out analysis so were also taken for stage 2 targeted sequencing (Table S2; Figures S1 and 1).Cell Metabolism 31, 1107–1119.e1–e12, June 2, 2020 e10
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To identify gene-based results driven by one ormore variants, we applied the following leave-one-out strategy: 1- among the variants
seen more than twice in our stage 1 sample (cases and controls together), we identified the variant with the lowest single-variant
analysis p value whenever it is nominally significant (p < 0.05); 2- we removed this variant and performed the stage 1 gene-based
test again. We repeated steps 1 and 2 until the stage 1 gene-based p value was above 0.1 or there were no additional variants
seen more than twice and with a single-variant analysis p value < 0.05. For genes that were driven by one or two single variants
(8 genes, Table S2; Figure S1), we genotyped single variants. Otherwise, we sequenced the coding region of the gene.
Stage1+2 Meta-Analyses
Gene-based meta-analysis was performed for 9 genes selected from stage 1 analysis and taken forward for targeted sequencing in
stage 2. This analysis was performed using the MetaSKAT_wZ function from the R package MetaSKAT (version 0.60, August 17,
2015) (Lee et al., 2013). For the LOF and STRICT analyses, we use the option r.corr = 1 to run a burden test, while for broad analysis,
we used the option method = ’’optimal’’ to run SKAT-O. All other MetaSKAT_wZ options were set to their default value.
Association Analysis Using External Controls
We used ProxECAT (Hendricks et al., 2018), to perform case-control analysis of the burden of LOF and STRICT very rare variants in
the gene region for 927 SCOOP cases versus 21,384 external common controls of non-Finnish European descent from gnomAD.
ProxECAT tests for a difference in the ratio of very rare functional variants (LOF or STRICT) to very rare synonymous variants between
cases and controls. Comparing the ratio of functional to synonymous variants enables the inclusion of external controls, but can
reduce power to detect an association. As this analysis uses the same set of cases from the stage 1 analysis, it is not a true replica-
tion, but can provide more evidence for or against an association given the different control sample. This can be especially helpful for
genes where there were no rare minor alleles identified in the controls from the stage 1 analysis (i.e., STRICT: ZNF32, HEPACAM;
LOF: ZMYM4, PHIP, VIL1) (Table S3).
Genotyping
Based on results from the stage 1 single-point analysis (47 variants, see below) and gene-based tests (14 variants, see below) (Fig-
ure S1), 53 variants were selected to take forward to stage 2 in an additional 1,810 SCOOP and 3,800 randomly-selected Fenland
samples. Of the 53 variants, 48 assays were successfully designed for Agena genotyping (Agena Bioscience) across 2 plexes.
Four SNPs failed QC resulting in 44 SNPs for single variant analysis. Sixty-two SCOOP cases and 23 Fenland controls with a call
rate below 0.9 were removed, resulting in 1,754 SCOOP cases and 3,777 Fenland controls for single-variant analysis in the stage
2 dataset.
Gene Set Enrichment
A summary of gene sets used is in Table S8.
Gene Sets
Obesity and Syndromic Obesity Gene Set
Genes known to harbor causal, highly penetrant mutations involved in human obesity were taken from Table 1 in Pigeyre et al. (2016)
(Tables S8A and S8B).
Developmental Disorder Gene2Phenotype Gene Set
The Developmental Disorder Gene2Phenotype (DDG2P) online system curates genes related to developmental delay and the
strength of evidence for the association between the gene and developmental delay. More details can be found here: https://
www.ebi.ac.uk/gene2phenotype. DDG2P gene annotation from July 23, 2017 was used for analysis (Tables S8B and S8C).
Constrained and Unconstrained Gene Set
All constraint metrics were from ExAC release 0.3.1 (Samocha et al., 2014) file: fordist_cleaned_nonpsych_z_pli_rec_null_data.txt.
Two gene sets were created a constrained gene set where pLI > 09 (Tables S8B and S8D) and an unconstrained gene set with genes
with pLI% 0.9.
Curated List of Known Obesity or BMI Association Genes
The NHGRI-EBI GWAS catalog (https://www.ebi.ac.uk/gwas/, accessed on 25th July 2017) was used to extract a list of obesity/BMI
signals, reaching genome-wide significance (p value < 5x108) in Europeans using the search terms ‘‘BodyMass Index,’’ ‘‘Childhood
body mass index,’’ ‘‘Obesity,’’ ‘‘Obesity (extreme)’’ and ‘‘Obesity (early onset extreme).’’ Using the reported gene for each signal, we
identified 157 unique genes (Tables S8B and S8E).
We performed gene set enrichment analysis similar to previous analyses (Purcell et al., 2014; Singh et al., 2016). Gene set analysis
was performed on five primary groupings, each of which had subsets, resulting in 10 primary gene sets for analysis (Table S9B). We
repeated primary analysis in patients with obesity and developmental delay (Table S9C) and with obesity alone (Table S9D). A sec-
ondary analysis was performed to assess genes that were both LOF constrained (i.e., pLI > 0.9) and GWAS (Table S9E).
Briefly, using PLINK/SEQ (https://atgu.mgh.harvard.edu/plinkseq/index.shtml) we calculated gene region test-statistics for an
enrichment of genetic variants in cases compared to controls. For each gene, we evaluated the three analysis groupings used in
the gene-based tests: BROAD (MAF < 1% and broadly damaging), STRICT (MAF < 0.025% and strictly damaging), and LOF
(MAF < 0.025% and LoF). We then used the SMP utility to calculate the gene set enrichment while controlling for exome-wide dif-
ferences between cases and controls. Twenty thousand case control permutations were used to estimate the empirical gene sete11 Cell Metabolism 31, 1107–1119.e1–e12, June 2, 2020
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tigated within each analysis grouping (i.e., BROAD, STRICT, and LOF). A Chi-square test of Independence was used to compare the
overlap of genes in the GWAS gene set that were also LOF constrained.
Functional Work Statistical Analysis
Distributions of average nuclei/cytoplasm ratio were compared between PHIP functionally studied variants seen only in cases and
variants seen in controls by a Wilcoxon rank sum test.
Mouse Statistical Analysis
For all analyses, the individual mousewas considered the experimental unit within the studies. All mutant data (7 females and 7males)
from the pipeline was collected across multiple batches and were compared to a year’s worth of overlapping control data collected
on mice from the same genetic background (up to 226 females and 231 males) for DEXA, ipGTT and CC (total 43 parameters). As a
high-throughput project, the target sample size of 14 mutant animals per strain is relatively low. This was determined after a com-
munity-wide debate to find the lowest sample size that would balance resource usage while detecting phenotypic abnormalities.
For analysis of continuous data, the current work uses linear mixed models to allow modeling of multiple sources of variability on
a phenotype. The approach was previously discussed by Karp and colleagues (Karp et al., 2012) as a way of integrating factors
like genotype (G), sex (S) and genotype*sex (G*S) when performing phenotypic analysis of the mice. These factors are assumed
to have a fixed values. Given our multi-batch experimental design strategy, linear mixedmodels also allow us to include batch effects
as a random effect, with the assumption that animals from the same batch will have correlated phenotypes. This arises from factors
such as technician skill, reagent lot, cage environment, maternal ability and genotype, and litter size. In the study of Karp and col-
leagues (Karp et al., 2012) two equations were put forward: Equation 1 (below) includes G, S and G*S and batch effect as described.
Equation 2 is similar to Equation 1 but includes body weight as an additional factor affecting phenotype.YGenotype + Sex + Genotype*Sex + (1|Batch) (Equation 1)
We used Equation 1 here since body weight is one of the phenotypes that we are interested in measuring and since body weight
does not scale linearly (or at all) with many of the parameters that we are testing in our global phenotypic screen. Analysis were per-
formed using PhenStat (Kurbatova et al., 2015), an R package version 2.18.0 available from Bioconductor (Gentleman et al., 2004).
The package’s mixed model framework was used as default except the argument equationType was set to withoutWeight and data-
PointsThreshold was set to 2. The genotype contribution test p value was adjusted for multiple testing to control the false discovery
rate to 5%. This statistical method has been studied through simulations and resampling studies (Karp et al., 2014) and found to be
robust and reliable with amulti-batch workflow, where the knockout mice are split intomultiple phenotyping batches. All statistics are
shown in the corresponding figures (Figures S6 and S7) and corresponding figure legends.
Expression Data
Expression data and corresponding plots (Figure S3) were obtained from https://gtexportal.org/home/.Cell Metabolism 31, 1107–1119.e1–e12, June 2, 2020 e12
